In June 2020, BSV formed a strategic alliance with LaVoieHealthScience in order to enhance BSV's capabilities to communicate value. <read more here>                     In May 2020, BSV entered into a strategic alliance with FCF Fox Corporate Finance to support funding activities. <read more here>                    
                           COVID-19 Portal               Home      About      Team      Clients      Publications      Downloads      News      Career      Contact

  With the dedicated support, and particularly the experienced, constructive work of Bioscience Valuation, we accomplished meaningful results that provide important new knowledge enabling our next steps in diabetes research. We sincerely thank the entire Bioscience Valuation team for their valuable and straightforward collaboration in the past year, and look forward to the next opportunity of working with them again.

Prof. Dr. Thomas Danne, Director, and Dr. Bärbel Aschemeier, Clinical Research, AUF DER BULT Hospital for Children and Adolescents


Core Services
  Financial Valuation
  Commercial Assessment &

  R&D Risk Analysis &
Productivity Increase

  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

Comprehensive Support
  Corporate Partnership Program

  Market Model
  R&D Risk Model
  Valuation Model

Special Expertise - Assessing the Economics of Personalized Medicine

In Personalized (stratified) Medicine the selection of optimal treatment depends on a patient's genetic makeup. Typically, the presence or absence of a biomarker predicts the response to a particular therapy. Certain personalized treatments may produce savings to payers, while others may increase costs.

It is not well understood whether more widespread use of personalized medicine will, overall, reduce or increase spending. Bioscience Valuation is a specialist in assessing the economics of personalized medicine. BSV may support ist clients to

  • analyze the economic impact of a particular personalized treatment on the healthcare system,
  • determine the cost-effectiveness of companion diagnostics and personalized drugs,
  • support price finding for personalized medicines,
  • assess the economics of investing in personalized medicine (net benefit of reduced attrition rates and decreased trial size, but smaller markets and additional effort to develop a companion diagnostic).

A major European investment bank wished to determine risks and potential returns of investing in companies that are active in the development and marketing of personalized medicine. Bioscience Valuation analyzed effectiveness, safety and pricing, among other parameters, of current personalized treatments to determine benefits and costs for patients, physicians and payers.

Furthermore, BSV assessed the economics of R&D investment from pharma's point of view. Market sizes shrink (through stratification of patients) and the development of companion diagnostics generates additional costs; however, personalized drugs are generally sold at a premium and may reduce clinical development costs (for the Rx) as well as attrition rates. The comprehensive Bioscience Valuation report illustrates chances and risks for all stakeholders.

This website uses cookies to ensure you get the best experience on our website.
Privacy Policy